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Abstract
Objective—To describe patterns of suboptimal immune recovery (SO-IR) and associated HIV-
related-illnesses during the first 5 years following first-line antiretroviral therapy (ART) initiation 
across seven ART sites in East Africa.
Design—Retrospective analysis of data from seven ART clinical sites (three Uganda, two Kenya 
and two Tanzania).
Methods—SO-IR was described by proportions of ART-treated adults with CD4+ cell counts less 
than 200, less than 350 and less than 500 cells/μl. Kaplan–Meier survival analysis techniques were 
used to assess predictors of SO-IR, and incident rates of HIV-related illnesses at CD4+ cell counts 
less than 200, 200–350, 351–499, and >500 cells/μl, respectively.
Results—Overall 80 843 adults initiated non-nucleoside reverse transcriptase inhibitor-based 
first-line ART; 65% were women and median CD4+ cell count was 126 [interquartile range (IQR), 
52–202] cells/μl. Cumulative probability of SO-IR <200 cells/μl, <350 cells/μl and <500 cells/μl, 
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after 5 years, was 11, 38 and 63%, respectively. Incidence of HIV-related illnesses was higher 
among those with CD4+ cell counts less than 200 and 200–350 cells/μl, than those who achieved 
CD4 counts above these thresholds. The most common events, at CD4 <200 cells/μl, were 
pulmonary tuberculosis [incident rate 15.98 (15.47–16.51)/100 person-years at risk (PYAR), oral 
candidiasis [incident rate 12.5 (12.03–12.94)] and herpes zoster [incident rate 6.30 (5.99–6.64)] 
events/100 PYAR. With attainment of a CD4+ cell count level 200–350 cells/μl, there was a 
substantial reduction in events/100 PYAR – by 91% to 1.45 (1.29–1.63) for TB, by 94% to 0.75 
(0.64–0.89) for oral candidiasis, by 84% to 0.99 (0.86–1.14) for Herpes Zoster, and by 78% to 
1.22 (1.07–1.39) for chronic diarrhea. The incidence of all events decreased further with CD4 
counts above these thresholds.
Conclusion—Around 40% of adults initiated on ART have suboptimal immune recovery with 
CD4 counts <350 cells/ml after five years. Such patients will require closer monitoring for both 
HIV-related and non-HIV-related clinical events.
Keywords
cART; first-line antiretroviral therapy; HIV-related illnesses; immune recovery; Kenya; sub-
Saharan Africa; Tanzania; Uganda
Background
The global scale up of antiretroviral therapy (ART) has shown remarkable progress during 
the last decade, with now more than 15 million individuals receiving ART [1,2]. The greatest 
increase has occurred in sub-Saharan Africa (SSA), where more than 11 million have 
received ART [2]. As of July 2014, ART has been associated with a 35% decline in AIDS-
related mortality to approximately 1.7 million, compared with 2005 (and a 32% decline in 
SSA), although the region still accounts for 70% of all persons dying from AIDS [1,2]. This 
has been made possible through adoption of a public health approach to treatment scale up, 
whereby the implementation of simplified and standardized approaches (such as simplified 
treatment regimens as part of fixed-dose combinations, and decentralization of services) 
ensures the widest possible access to high-quality services at the population level [3].
There has been a steady increase in the median CD4+ cell count at ART initiation in SSA 
[4,5], in accordance with successive WHO guidelines, less than 200 cells/μl in 2006 [6], less 
than 350 cells/μl in 2010 [7], less than 500 cells/μl in 2013 [8], and now ‘treat all’ regardless 
of CD4+ cell count in 2015 [9]. However, late presentation and diagnosis remains common 
in many settings, and so ART is often initiated when disease is already advanced and CD4+ 
cell counts are well below the recommended threshold. Late initiation of ART is associated 
with a high risk of early mortality, mainly due to HIV-related opportunistic infections 
especially in the first year before there has been sufficient time for adequate immune 
reconstitution, but also due to ART-related immune reconstitution inflammatory syndrome 
[10–12].
Although data on the distribution of the CD4+ cell count at ART initiation in adults is well 
documented in the literature [3,5,10], the subsequent CD4 response has been less well 
described, and in particular the proportion that remain profoundly immunosuppressed and at 
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risk for opportunistic infections. Factors associated with sub-optimal immune recovery (SO-
IR) include older age [11–14], gender [15–18], advanced HIV disease at ART initiation [19], 
coinfections such as tuberculosis (TB) [20], hepatitis C [19] and persistent immune 
activation [13–15], and it is presumed to be mediated by severe HIV-associated immune 
dysfunction [21–23]. Even those who immune reconstitute to above 200 cells/μl (the level 
above which they are at a substantially lower risk of opportunistic infections) but below 500 
cells/μl remain at risk for non-AIDS-defining events such as liver, cardiovascular and renal 
diseases [24], and other comorbidities due to persistent immune activation [24–27]. 
Moreover, a recent landmark the Strategic Timing of Anti-Retroviral Therapy trial (START) 
showed that starting ART when the CD4+ cell count is above 500 cells/μl (compared with 
<350 cells/μl) more than halved the risk of AIDS events, deaths as well as serious non-AIDS 
events [28].
A range of definitions have been used to determine SO-IR at different time points after ART 
initiation. These include a magnitude of CD4+ cell count increase of less than 50 cells/μl 
after 6 months [29], or less than 100 cells/μl after 12 months [12,30], and an absolute CD4+ 
cell count remaining below 200 cells/μl after 24 months [31,32], or below 500 cells/μl after 
60 months [33] as well as variations in longitudinal analyses [34]. Understanding the 
proportion of patients who fail to attain CD4+ cell count levels above 200, 350 and 500 cells/
μl has important programmatic implications. Those patients with SO-IR, and particularly 
CD4+ cell counts less than 200 cells/μl will require closer monitoring for the development of 
AIDS-defining and non-AIDS-defining clinical events, as well as more prolonged 
prophylaxis (e.g. with cotrimoxazole and isoniazid). The objective of our analysis was three-
fold: first, to quantify the proportion with a CD4+ cell count below 200, 350 and 500 cells/μl 
(reflecting the incremental WHO thresholds for ART initiation) during the first 5 years post-
ART initiation; second, to describe clinical consequences of SO-IR and, third, to identify 
factors associated with suboptimal immune response.
Methods
Study setting and participants
The International epidemiologic Databases to Evaluate AIDS (IeDEA) network is an 
international research consortium, established in 2005 by the National Institute of Allergy 
and Infectious Diseases, that pools data from geographically dispersed cohorts to address 
regionally important epidemiological and HIV programmatic questions. Cohorts from all 
seven sites in the IeDEA East African region were included in this analysis, and dates of last 
available data or database closure are given in parentheses. These included three sites in 
Uganda, Mbarara Immune Suppression Syndrome Clinic (31 December 2009), Masaka 
Regional Hospital HIV Clinic (13 June 2011) and Infectious Diseases Institute, Makerere 
University (24 May 2011), two programs in western Kenya: Academic Model Providing 
Access to Healthcare (AMPATH) sites (27 July 2011) and Family AIDS Care and Education 
Services (FACES) sites (30 May 2011), and in Tanzania, Ocean Road Cancer Institute – 
(ORCI) (14 July 2010), and Tumbi Special Hospital (18 September 2008). Analysis was 
conducted on de-identified data, and patients were not individually consented to participate. 
All research in IeDEA is overseen by institutional review boards or ethics committees in the 
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countries where data are collected, and by ethics committees with oversight over the 
analytical teams [4,5].
Within this region, we included all adult patients (≥18 years at ART initiation) enrolled at 
one of the East Africa sites, who initiated an ART regimen that contained at least three drugs 
(according to the national HIV treatment guidelines), and had received at least 6 months of 
ART and remained in care. At the time, patients were initiated on stavudine, lamivudine/
zidovudine and nevirapine/efavirenz, with efavirenz given mainly for patients with TB and 
lamivudine for patients with hemoglobin levels below 8 g/dl; and one-drug regimen switches 
were recommended in cases of drug toxicities. Sociodemographic and clinical variables such 
as sex, age, ART regimen, and the dates of clinical events (ART initiation, follow-up visits 
and HIV-related illnesses including but not limited to oral and esophageal candidiasis, 
pulmonary TB, chronic diarrhea, herpes zoster eruptions, Kaposi’s sarcoma, cryptococcal 
meningitis, Pneumocystis carinii pneumonia and papular pruritic eruptions), and CD4 
measurements collected during the course of routine care (generally every 6 months) were 
available for analysis. Adherence support was provided routinely and patient adherence to 
ARTwas self-reported at 95% at least within the ART programs. Routine viral load 
monitoring was not available in the sites at the time of analysis.
Data analysis
Definition of suboptimal immune recovery—A variety of different definitions have 
been used in clinical trials [33,34], observational cohorts [31,32], pathogenesis studies 
[19,35] to define suboptimal recovery. In this analysis, we defined SO-IR as failure to attain 
three different CD4+ cell count thresholds during the first 5 years of first-line antiretroviral 
therapy: 200 cells/μl (SO-IR200), below which individuals remain at particular risk of life-
threatening opportunistic infections [22,23]; 350 cells/μl (SO-IR350) – the recommended 
threshold for ART initiation in the WHO 2010 guidelines [7] and 500 cells/μl (SO-IR500) – 
the recommended threshold for ART initiation in WHO 2013 guidelines [9]. CD4+ cell 
counts above 500 cells/μl are considered normal relative to the average CD4+ cell counts of 
≥500 cells/μl among healthy Africans [36]. Baseline CD4+ cell count at ART initiation was 
defined as the most recent CD4+ cell count in the 2 months prior to ART initiation and a 
follow up CD4+ cell count was defined as the most recent CD4+ cell count within 2 months 
before and after the respective analysis time. Baseline variables at ART initiation included in 
the model were sex, age, BMI, WHO clinical stage, CD4+ cell count and ART regimen. 
Proportions of ART-treated patients in the three categories of SO-IR were calculated during 
the first 5 years of the ART programs.
Opportunistic infections and suboptimal immune recovery—Kaplan–Meier 
survival analysis techniques were used to assess the cumulative probability of suboptimal 
immune recovery, with competing risks of death or loss to followup. Using survival analysis, 
the incidence rates of HIV-related opportunistic infections and related illnesses during the 
first 5 years following ART initiation were obtained, and reported for the period (below the 
CD4+ cell count thresholds of 200, 200–350, 351–499 cells/μl and >500 cells/μl. Individuals 
were censored at switch to second-line ART, death, loss to follow-up (defined as those with 
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no clinic visit 6 months or more prior to database closure), database closure and at 
attainment of CD4+ cell counts 200–350 and 351–499 cells/μl for the respective analyses.
The respective rates of HIV-related illnesses among these CD4 strata were expressed as 
incidence rates per 100 PYAR, with 95% confidence intervals (CIs). Reductions in incidence 
rate (after attainment of the different CD4 thresholds) were expressed as percentage 
reductions. Predictors of SO-IR, using the three thresholds, were determined in a Cox 
proportion hazard model. Missing data on baseline CD4+ cell count were imputed using 
chained equations. All analysis was carried out using STATA 12 (Copyright 1985–2011. 
StataCorp LP, College Station, Texas, USA).
Results
Patients eligible for inclusion in analysis of rate of suboptimal immune recovery
Overall, 83 926 initiated ART at the seven IeDEA sites in East Africa, of whom 3083 (3%) 
were excluded because records showed that they had initiated less than three antiretroviral 
drugs. Each year, between 9 and 32% of patients were lost to follow-up, with the highest 
numbers lost to follow-up in the first 3 years after ART initiation. Between 21 and 64% of 
the patients in care at each of the respective time points were not eligible for analysis of SO-
IR because they did not have a CD4+ cell count measurement at or within 2 months before 
and after the respective time point (Table 1).
Patient characteristics at antiretroviral therapy initiation
Of the 80 843 patients initiating a triple antiretroviral drug regimen, 65% were women, and 
at ART initiation, the median age was 36 years; interquartile range (IQR) (30–43), BMI 
median was 20.1 kg/m2 (IQR, 17.9– 22.5), median CD4+ cell count was 126 cells/μl (IQR, 
52–202), median hemoglobin was 11.3 g/dl (IQR, 9.7– 12.9). The majority (97%) initiated 
an non-nucleoside reverse transcriptase inhibitor-based regimen. Baseline demographic and 
clinical characteristics at ART initiation were similar across the three countries, but Tanzania 
had a low hemoglobin level: 9.6 g/dl (7.9–11.4) versus 11.2 g/dl (9.6–12.8) and 11.7 g/dl 
(10.2–13.1) for Kenya and Uganda respectively, although the differences were not 
statistically significant (Table 2).
Cumulative proportion with suboptimal immune recovery
Overall, the proportions of ART-treated adults with SO-IR declined as absolute CD4+ cell 
counts increased over the duration of ART. The proportion with CD4+ cell counts less than 
200 cells/μl reduced from 36% after 6 months of ART to 20% after 24 months and 11% after 
60 months, and the proportion with a CD4+ cell count less than 350 cells/μl reduced from 
71% after 6 months of ART to 58% after 24 months and 38% after 60 months, and those 
with CD4+ cell counts less than 500 cells/μl reduced from 89% after 6 months of therapy to 
80% after 24 months and 63% after 60 months of therapy (Table 3).
HIV-related illnesses before and during immune recovery
Using survival analysis techniques, we examined the cumulative probability of SO-IR 
[remaining with CD4+ cell count thresholds below 200 cells/μl SO-IR200], between 200 and 
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350 cells/μl SO-IR 350 and between 351 and 500 cells/μl SO-IR 500 at each year during the 
first 5 years following ART initiation, taking into account the competing risks of death and 
loss to follow-up. Overall, there was 132 356 PYAR with CD4 cells counts less than 200 
cells/μl, 127 758 PYAR >200 ≤ 350 cells/μl, and 105 823 PYAR > 350 ≤ 500 cells/μl.
The most common opportunistic infections prior to achieving CD4+ cell count threshold 
above 200 cells/μl were pulmonary TB [incident rate, per 100 person-years (95% CI), 15.98 
(15.47–16.51)] oral candidiasis [12.5 (12.03–12.94)], herpes zoster [6.30 (5.99–6.64)] and 
chronic diarrhea [5.48 (5.18–5.78)]. After attainment of a CD4+ cell count threshold above 
200 cells/μl (between 200 and 350 cells/μl), there was a substantial reduction in event rates 
of opportunistic infection events by 91% to 1.45 (1.29–1.63) for TB, by 94% to 0.75 (0.64–
0.89) for oral candidiasis, by 84% to 0.99 (0.86–1.14) for herpes zoster, and by 78% to 1.22 
(1.07–1.39) for chronic diarrhea (Table 4).
When the CD4+ cell count > 350 < 500 cells/μl strata was considered, pulmonary TB, 
chronic diarrhea and pruritic purpura eruptions were the commonest HIV-related events at 
incident rates of 1.05 (0.87–1.27), 1.08 (0.89–1.31) and 1.11 (0.92–1.34), respectively. After 
attainment of CD4 counts CD4 >500 cells/μl, AIDS related events such as pneumocystis 
carinii pneumonia, cryptococcal meningitis, extrapulmonary TB and toxoplasmosis were not 
observed (Table 4).
Factors associated with suboptimal immune recovery
In a multivariate analysis model we identified factors associated with SO-IR. Factors 
significantly associated with SO-IR200 were older age (every 5 year increase in age), sub-
hazard ratio (SHR) [95% CI, 1.01 (1.00–1.03), male gender, SHR 1.14 (1.08–1.20), baseline 
CD4+ cell count less than 100 cells/μl versus more than 100 cells/μl, SHR 0.89 (0.80–0.99), 
and hemoglobin level below 10 mg/dl versus 10 mg/dl and above, SHR 1.39 (1.29–1.48)], as 
shown in Table 5. The risk factors that were significant and magnitude of effect were similar 
across the different SO-IR CD4+ cell count thresholds of 200, 350 and 500 cells/μl. Baseline 
weight above 60 kg had a modest but statistically significant association with SO-IR 350 
[SHR 1.04 (1.01–1.08)] and SO-IR 500 [SHR 1.05 (1.02–1.07)].
Discussion
This analysis of around 80 000 HIV-infected persons from HIV care programs in Kenya, 
Uganda and Tanzania who initiated mainly non-nucleoside reverse transcriptase inhibitor-
based ART regimens between 2005 and 2011 at a median CD4+ cell count of 126 (52–202) 
cells/μl, represents the most comprehensive study of the frequency and consequences of 
suboptimal immune reconstitution to date. At 12 months, 29% of ART-treated patients in 
care with follow-up CD4+ cell counts (±within 2 months), had suboptimal immune recovery 
(SO-IR) with CD4+ cell counts less than 200 cells/μl, 66% and 87% had SO-IR with CD4+ 
cell counts below 350 and 500 cells/μl, respectively. Proportions of SO-IR declined with 
increasing duration of ART to 11% below 200 cells/μl, 38% below 350 cells/μl and 63% 
below 500 cells/μl, after 5 years of ART.
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SO-IR was associated with high rates of HIV-related opportunistic and other illnesses, and 
the commonest events were pulmonary TB, oral candidiasis and herpes zoster, followed by 
papular pruritic eruptions, chronic diarrhea, recurrent respiratory tract infections, esophageal 
candidiasis, Kaposi’s sarcoma, chronic herpes simplex and pneumocystis pneumonia. In our 
current study, immune recovery to at least 200–350 cells/μl was associated with over 90% 
reduction in incidence of all opportunistic infections to an incidence rate of less than 1 per 
100 person-years for all reported events except TB, chronic diarrhoea papular pruritic 
eruptions and respiratory tract infections. A similar pattern was observed for opportunistic 
infections in other CD4+ cell threshold categories. Although in a previous analysis from one 
of the clinic sites in Uganda, we reported comparable HIV-related events among optimal and 
suboptimal responders in the Infectious Diseases Institute (IDI) research cohort in Uganda, 
the latter study was based on only 380 persons with 123 events during a 2-year period of 
follow-up [31]. Therefore, using data from seven IeDEA sites, including IDI, substantially 
increased the statistical power to detect a higher incidence of opportunistic infections among 
SO-IR compared to optimal immune responders (OP-IR).
Other studies have shown similar rates of CD4+ cell counts persisting below 200 cells/μl, 
350 and 500 cells/μl, and a continued high rate of clinical events during ART [32–34,37,38]. 
Even in settings where there is routine monitoring of viral load, data show that although the 
majority of those who are virologically suppressed achieve good immune recovery, up to 
40% still exhibit SO-IR [39,40]. In the United Kingdom Collaborative HIV cohort study 
[34], ART-treated patients with CD4+ cell counts 350–499 cells/μl had an opportunistic 
infection rate of 2.49 per 100 person-years, which was reduced to a rate of 1.54 per 100 
person-years in those with a CD4+ cell count 500–649 cell/μl and 0.96 per 100 person-years 
among those with CD4+ cell counts above 650 cells/μl. In another multicenter study in 
Europe, ART-treated patient with suboptimal immune recovery (CD4 reported to gain of less 
than 50 cells after 1 year) had higher post-ART mortality of 3.22 per 100 person-years 
versus 0.71 per 100 person-years among optimal immune responders [41]. Similarly, among 
850 participants in a community program in the United States during a 5-year follow up 
period, both AIDS and non-AIDS disease rates declined from 13.8 to 2.1 events per 100 
person-years when the most recent CD4 cell count increased from less than 200 to 200 cells/
μl and from 2.0 to 1.7 events per 100 person-years when the latest CD4+ count increased 
from 200 to 350 cells/μl to more than 350 cells/μl [24].
We found that individuals with advanced HIV disease (WHO clinical stage 3 and 4, and 
CD4+ cell count <100 cells/μl) were less likely to have SO-IR (SO-IR200, SO-IR350 and 
SO-IR500). This finding was similar to our previous report from IDI (one of the contributing 
sites) where pre-ART CD4+ cell count ≥100 cells/μl was associated with suboptimal 
immune recovery (CD4+ cell count increase <50 cells/μl after 6 months and CD4+ cell count 
increase <200 cells/μl after 24 months of ART), when compared with individuals with pre-
ART CD4+ cell counts less than 100 cells/μl [31]. Similarly, in the IDI cohort, individuals 
with pre-ART CD4+ cell counts of 50–199 cells/μl were three times more likely to have 
suboptimal immune recovery than those with pre-ART CD4+ cell counts less than 50 cells/μl 
[31]. Our results are also consistent with previous reports from South Africa where 
individuals with pre-ART CD4+ cell counts less than 50 cells/μl had better CD4+ cell count 
recovery during 48 weeks of ART compared to those with higher pre-ART CD4+ cell counts 
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[11]. Additional evidence from three large HIV treatment programs in South Africa, showed 
that patients with pre-ART CD4+ cell counts less than 50 cells/μl had a steeper gradient of 
CD4+ cell count increase than patients with pre-ART CD4+ cell counts between 50 and 199 
cells/μl [42]. The high CD4+ cell count recovery in these studies could be attributed to 
peripheral expansion and/or redistribution of CD4 T cells that is described in the initial 
phase of CD4 recovery during antiretroviral therapy [43]. Our findings are contrary to 
reports from the Australian HIV Observational database where higher baseline CD4 T-cell 
counts predicted attainment of a CD4+ cell count more than 500 cells/μl [44].
Advanced HIV disease has been previously associated with high collagen deposition and 
irreversible fibrosis of the reticuloendothelial system, leading to poor immune recovery 
[19,22,23]. In addition, coinfections including hepatitis C virus, genetic polymorphisms and 
differences in regulatory T-cell function and homeostasis have been suggested to contribute 
to poor CD4 T-cell recovery during ART [19]. We postulate that CD4+ cell counts may not 
be the best measure of immune recovery, particularly among individuals with advanced HIV 
disease in Africa. There is need to understand the role of other biomarkers of HIV disease 
progression, such as immune activation and microbial translocation markers [45], in 
enhancing the monitoring of immune recovery among individuals in SSA that initiate ART 
at advanced stages of disease. Measurement of HIV reservoir size could also provide 
additional evidence on response to ART, given the direct correlation of cell-associated HIV 
RNA with immune activation among ART-treated individuals [46].
Other factors with smaller impact on SO-IR were increased age (2–4% increased risk for 
each 5-year increase in age), and weight more than 60 kg. A less optimal immune response 
with increased age has also been reported in other studies, and among individuals older than 
30 years of age [5,34], due to diminished thymus function with advancing age [5]. Similarly, 
other studies have reported an association between age greater than 30 years and poorer 
long-term immune response to ART [10,11], including an analysis of persons who had 
achieved viral suppression [8]. Patients with weight more than 60 kg at ART initiation were 
more likely to have SO-IR, although we were unable to use BMI due to incomplete height 
records. Previous reports from the North American AIDS Cohort Collaboration on Research 
and Design (NA-ACCORD) cohort suggest that a BMI of approximately 30 kg/m2 at ART 
initiation was associated with greater CD4 T-cell recovery at 12 months compared with 
higher or lower BMI values, suggesting that body composition may affect peripheral CD4 T-
cell recovery [47]. We therefore recommend consistent follow-up of BMI in African HIV 
treatment cohorts to further understand its role in host immune recovery during ART.
A key limitation and striking finding in this analysis of routinely collected data from 80 000 
persons, who initiated ART across multiple sites in East Africa, is that 21–64% of patients in 
care, depending on site, had no record of follow-up CD4+ cell count measurements at the 
different follow-up time points, and were therefore excluded from the analysis of suboptimal 
immune recovery. Although, we found no systematic differences in demographic or clinical 
characteristics of those with missing data, we speculate that these persons may be more 
likely to have suboptimal responses and therefore the true prevalence of suboptimal immune 
recovery may have been underestimated. This also highlights the real-world challenges of 
optimal data collection in resource-limited settings, and importance of strategies to optimize 
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retention in care to achieve full impact of ART scale up. Second, there was no routine 
monitoring of viral load in our study population, so we were not able to describe underlying 
treatment failure and development of drug resistance as independent causes of SO-IR. This 
retrospective data analysis did not evaluate innate host factors that may contribute to slow 
immune recovery. Additional strategies of ART regimen optimization or immune 
modulatory interventions may require formal evaluation [48].
What are the implications of these findings for antiretroviral programs?
First, a high proportion (around 40%) of patients initiated on ART in the absence of routine 
viral load monitoring did not achieve optimal immune recovery to at least a CD4+ cell count 
greater than 350 cells/μl and remained at risk of HIV-related opportunistic and other 
infections. Such patients may require closer monitoring for the development of HIV-related 
as well as non-HIV-defining clinical events, and consideration for long-term prophylaxis 
with cotrimoxazole and isoniazid. There is now an increasing emphasis on strategic use of 
viral load monitoring rather than CD4+ cell count monitoring to assess response to ART and 
identify treatment failure early on, for individuals that require ART regimen switch to 
second-line ART [9,32,37]. Multiple studies have shown that when sustained viral 
suppression is achieved, there is good immune recovery [10,49]. Among 1004 patients ART-
treated patients attending the Melbourne Sexual Health Centre in Australia, routine CD4+ 
cell counts rarely influenced clinical decisions to stop or change treatment therefore CD4+ 
cell count monitoring was reduced from biannual to annual [50].
However, the significant proportion with SO-IR and ongoing HIV-related events in our 
cohort should caution ongoing discussions in countries about discontinuation of CD4+ cell 
count monitoring [45], particularly if patients have not attained CD4+ cell counts more than 
500 cells/μl. Strategic monitoring of CD4+ cell count will be needed to identify those 
patients who remain at risk of opportunistic infections due to SO-IR based on readily 
available measures such as white blood cell count and lymphocyte percentage [44] or poor 
adherence [20,43]. Predictive models to identify those who will remain with a CD4+ cell 
count less than 200 cells/μl in the first 3 years of therapy [44] could be used to prioritize 
CD4+ cell count and viral load measurements for those with SO-IR who may require 
adherence support or switch to second-line ART.
The database for these analyses did not include follow-up of patients that were not receiving 
ART. It is evident, however, that the opportunistic infections presented here could occur at 
higher CD4+ cell counts, for example, TB, oral candidiasis, and herpes zoster.
Our findings, emphasize the importance of earlier ART initiation as a priority to improve 
clinical outcomes since patients with SO-IR remain at risk of AIDS-related events. The 
Strategic Timing of Antiretroviral Treatment and TEMPRANO ANRS 12 136 trials have 
demonstrated the profound impact of early ART at a CD4+ cell count above 500 cells/μl 
compared to when the CD4+ cell count declines to below 350 cells/μl [28,51], and 
international guidelines now recommend ART in all HIV infected persons regardless of 
CD4+ cell count [9,52,53]. However, even with continued progress of ART at any CD4+ cell 
count level in SSA [1,2], and the anticipated better immune recovery [4,33], some patients 
continue to initiate ART late and remain at greater risk of SO-IR. Given that all our patients 
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initiated zidovudine/stavudine containing regimen (according to the ART guidelines and 
availability at the time), there is need to evaluate long-term immune recovery with the 
recommended newer drugs that are less toxic [1]. It is also important to note that these 
analyses were limited to patients on first-line therapy and did not provide data on CD4 
trajectory after treatment switch to second-line therapy following immunological failure. 
Similarly, this study did not analyze the effects of one-drug regimen switches due to drug 
toxicities, given that adherence was not altered to levels below 95%. Our results, however, 
remain important to ART programs in SSA since duration of first-line ART is an indicator of 
the success of ART programs, in addition to immunological/virological responses, survival, 
treatment adherence and retention in care [54].
Conclusion
Around 40% of ART-treated adults in East Africa had suboptimal immune recovery with 
CD4 counts <350 cells/μl after the initial 5 years of first-line antiretroviral therapy, and this 
was associated with ongoing incident HIV-related illnesses. This has important 
programmatic implications, as these patients require closer monitoring for the development 
of HIV-related and non-HIV-related clinical events, as well as continued chemo-prophylaxis.
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Table 1
Cohort description of antiretroviral therapy-treated adults eligible for inclusion in 
analysis for 60 months of follow-up after antiretroviral therapy initiation.
83 926 initiated ART (of whom 3083 with less than drugs were excluded)
Follow-up time (months)
In care LTFUa
In care without a CD4+ 
cell countb
In care with CD4+ cell 
countc
In care with pre-ART 
CD4+ and follow-up CD4+ 
cell countd
n (%) n (%) n (%) n (%) n (%)
0 80 843
6 65 930 (82) 14 913 (18) 13 851 (21) 29 050 (44) 23 029 (35)
12 54 923 (68) 25 920 (32) 15 316 (28) 22 347 (41) 17 260 (31)
24 39 547 (49) 15 376 (19) 15 257 (39) 14 058 (36) 10 232 (26)
36 26 675 (33) 12 872 (16) 16 192 (61)   6037 (23)   4446 (17)
48 18 322 (23)   8353 (10) 13 245 (72)   2024 (11)   3053 (17)
60 10 423 (13) 7899 (9)   6712 (64)   2149 (21)   1562 (15)
ART, antiretroviral therapy; LTFU, loss to follow-up.
a
LTFU (individuals who have not had a clinic visit for 6 months and were excluded from the analyses) the percentage is among all patients initiated 
on three-drug first-line ART regimen.
b
Patients in care without a CD4+ cell count within 2 months of time point, excluded from the analyses. The percentage is among all patients in care 
at each time point.
c
Patients in care with CD4+ cell counts within 2 months of time point, the percentage is among all patients in care at each time point.
d
Patients in care with pre-ART CD4+ cell and a follow-up CD4+ cell count, the percentage is among all patients in care at each time point.
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Table 2
Characteristics at antiretroviral therapy initiation in 80 843 patients across seven 
programmes in Kenya, Uganda and Tanzania.
Baseline characteristics Overall n = 80 843
Kenya 2 programmes n 
= 61 109
Uganda 3 programmes n 
= 17 793
Tanzania 2 
programmes n = 1941
Female, n (%)a 52 158 (64.5) 39 299 (64.3) 10 978 (61.6) 1251 (64.5)
Age in years, median 
(IQR)
           36 (30–43)            36 (30–43)            35 (29–41)           38 (32–45)
BMI (kg/m2), median 
(IQR)
              20.1 (17.9–22.5)               19.9 (17.9–22.3)               20.8 (18.5–23.4)              21.5 (21.2–23.8)
Hemoglobin level (g/dl); 
median (IQR)
             11.3 (9.7–12.9)              11.2 (9.6–12.8)              11.7 (10.2–13.1)              9.6 (7.9–11.4)
CD4+ cell count (cells/μl), 
median (IQR)
             126 (52–202)              130 (56–208)            111 (39–187)           113 (44–188)
Prior ART use for PMTCT b299/50 277 (0.6)            219/39 299 (0.6)           80/10 978 (0.7)          n/a
First-line ART regimen
    NNRTI-based regimenc; 
n (%)
d78 106 (96.6) 58 833 (96.3) 17 332 (97.4) 1941 (100)
     PI-based regimen    2051 (2.5)    1770 (2.9)    281 (1.6)
    Triple NRTI     322 (0.4)     147 (0.2)       175 (0.98)
    Otherse      364 (0.5)      359 (0.6)           5 (0.03)
Sites in Kenya were Academic Model Providing Access to Healthcare (AMPATH) and Family AIDS Care and Education Services (FACES) sites, 
Uganda sites were Mbarara Immune Suppression Syndrome Clinic, Masaka Regional Hospital HIV Clinic and Infectious Diseases Institute, 
Makerere University, and Tanzania sites were Ocean Road Cancer Institute (ORCI) and Tumbi Special Hospital. ART, antiretroviral therapy; IQR, 
interquartile range; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; 
PMTCT, prevention of mother to child transmission.
a13 missing gender.
b1881 women had missing data on prior ART use for PMTCT.
cNNRTI-based regimen included all efavienz [16 888 (21.6%)] and nevirapine-containing regimens [61 622 (78.9%)]. All patients initiated 
zidovudine/stavudine containing regimen that were recommended and available at the time.
d404 had three-drug regimen with both nevirapine and efavirenz.
eOthers includes individuals with ART regimen containing more than active antiretroviral drugs (excluding those with boosted lopinavir).
AIDS. Author manuscript; available in PMC 2017 May 19.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Nakanjako et al. Page 16
Table 3
Suboptimal immune recovery during the first 5 years of antiretroviral therapy at seven 
sites in East Africa.
Months of follow-up
Number in care 
with CD4+ cell 
counts
Number and proportion 
with SO-IR < 200 cells/μl n 
(%)
Number and proportion 
with SO-IR <350 cells/μl n 
(%)
Number and proportion 
with SO-IR <500 cells/μl n 
(%)
  6 29 050 10 355 (36) 20 689 (71) 25 907 (89)
12 22 347   6376 (29) 14 684 (66) 19 369 (87)
24 14 058   2803 (20)   7699 (58) 11 213 (80)
36   6037     978 (16)   2851 (47)   4471 (74)
48   4024     578 (14)   1685 (42)   2721 (68)
60   2149     235 (11)    813 (38)   1355 (63)
SO-IR, suboptimal immune recovery.
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Table 4
Rates of HIV-related illnesses in four CD4 cell count strata during the first 5 years of first 
line antiretroviral therapy.
Type of HIV-related illness
CD4 < 200 cells/μl Rate 
per 100PYAR (95% CI)
CD4 200–350 cells/μl 
Rate per 100PYAR 
(95% CI)
CD4 351–500 cells/μl 
Rate per 100PYAR 
(95% CI)
CD4 >500 cells/μl 
Rate per 100PYAR 
(95% CI)
Pulmonary TB 15.98 (15.47–16.51) 1.45 (1.29–1.63) 1.05 (0.87–1.27) 0.98 (0.87–1.10)
Oral candidiasis 12.5 (12.03–12.94) 0.75 (0.64–0.89) 0.61 (0.47–0.78) 0.60 (0.54–0.72)
Herpes Zoster 6.30 (5.99–6.64) 0.99 (0.86–1.14) 0.84 (0.68–1.04) 0.60 (0.52–0.71)
Chronic diarrhoea 5.48 (5.18–5.78) 1.22 (1.07–1.39) 1.08 (0.89–1.31) 0.84 (0.71–0.91)
Esophageal candidiasis 1.98 (1.81–2.17) 0.20 (0.15–0.28) 0.14 (0.08–0.23) 0.15 (0.13–0.23)
Kaposi Sarcoma 1.82 (1.66–2.01) 0.30 (0.23–0.39) 0.18 (0.11–0.28) 0.13 (0.09–0.18)
Pneumocystis carinii pneumonia 1.86 (1.69–2.04) 0.30 (0.23–0.39) 0.14 (0.08–0.23) –
Cryptococcal meningitis 1.06 (0.93–1.20) 0.38 (0.30–0.47) 0.28 (0.19–0.40) –
Herpes Simplex Virus 1.43 (1.28–1.59) 0.32 (0.25–0.42) 0.18 (0.11–0.28) 0.18 (0.13–0.24)
Extrapulmonary TB 1.12 (1.00–1.27) 0.30 (0.23–0.39) 0.28 (0.19–0.40) –
Toxoplasmosis 0.51 (0.42–0.61) 0.09 (0.06–0.15) 0.04 (0.02–0.12) –
Pruritic purpura eruptions 3.33 (3.13–3.54) 1.61 (1.44–1.27) 1.11 (0.92–1.34) 0.97 (0.86–1.09)
Recurrent URTI 2.56 (2.39–2.74) 1.11 (0.97–1.27) 0.82 (0.66–1.01) 1.00 (0.89–1.13)
TB, tuberculosis, URTI, Upper respiratory tract infection.
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Table 5
Multivariate analysis of factors associated with suboptimal immune recovery among 
adults receiving first-line antiretroviral therapy at seven sites in East Africa.
CD4+ cell count (SO-IR 200) <200 
cells/μl
CD4+ cell count <350 cells/μl CD4+ cell count <500 cells/μl
(N=42 306) (N=52 762) (N=54 895)
Patient factors Sub-hazard ratio (95% 
CI)
P Sub-hazard ratio (95% 
CI)
P Sub-hazard ratio (95% 
CI)
P
Age per 5-year increase 1.01 (1.00–1.03)   0.026 1.04 (1.03–1.05) <0.001 1.04 (1.03–1.05) <0.001
Male gender 1.14 (1.08–1.20) <0.001 1.09 (1.05–1.12) <0.001 1.03 (1.00–1.05)   0.035
Baseline CD4+ cell count (cells/μl)a
    <100 0.89 (0.80–0.99) <0.001 0.72 (0.68–0.74) <0.001 0.74 (0.71–0.76) <0.001
    100–200 1.00 0.68 (0.65–0.71) <0.001 0.65 (0.63–0.67) <0.001
    ≥200 1.00 1.00
WHO clinical stage
    I–II 1.00 <0.001 1.00 <0.001 1.00 <0.001
    III–IV 0.79 (0.74–0.83) 0.72 (0.70–0.74 0.73 (0.71–0.75)
First-line cART regimen
    Triple-NRTI 0.83 (0.66–1.04)   0.104 0.72 (0.62–0.82) <0.001 0.73 (0.66–0.81) <0.001
    PI-based 0.68 (0.39–1.19)   0.176 0.79 (0.59–1.06)   0.117 0.86 (0.71–1.05)   0.148
    NNRTI-based 1.00 1.00 1.00
Baseline hemoglobin count (g/dl)
    <10 1.39 (1.29–1.48) <0.001 1.29 (1.24–1.34) <0.001 1.29 (1.26–1.33) <0.001
    ≥10 1.00 1.00 1.00
Baseline weight (kg)
    <60 1.00   0.181 1.00   0.008 1.00 <0.001
    ≥60 1.04 (0.98–1.10) 1.04 (1.01–1.08) 1.05 (1.02–1.07)
NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitors; antiretroviral 
therapy (ART).
a
The reference group for SO-IR200 is CD4+ cell count 100–200 cells/μl.
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